MoonLake Phase 2 ARGO trial meets primary endpoint; sonelokimab ACR50 46-47% vs placebo

MoonLake Immunotherapeutics

ACR50 achieved by 46% (60mg) and 47% (120mg) with induction at week 12 (p<0.01 vs placebo; ITT-NRI).
Key secondary endpoint PASI90 reached by 77% (60mg) and PASI100 by 58% (60mg) at week 12.
Discontinuation rate <4%; no new safety signals; oral candidiasis <2%, no IBD/MACE/SI/B.
Sonelokimab numerically outperformed adalimumab on primary and key secondary endpoints.
Company plans Phase 3 in PsA; end-of-Phase 2 regulatory meeting timing to be announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.